Alzheimer’s disease is a chronic neurodegenerative disease. It is caused by accumulation of amyloid plaques that can be found in the brains of patients suffering this condition. Plaques are mainly composed of Beta amyloid (Aβ) peptides: Aβ (1-40) and Aβ (1-42). Recent studies showed that two Beta Amyloid peptides (Aβ (1-40) and Aβ (1-42)) exist in brain tissues, cerebrospinal fluid (CSF) and plasma in patients suffering from Alzheimer’s disease. In particular, aggregated Aβ (1-42) is considered a validated biomarker for diagnosing Alzheimer’s disease. Therefore, screening Aβ42 Ligands that could prevent aggregation is critical for developing potential therapeutic treatments. In BioVision’s Beta Amyloid 1-42 (Aβ42) Ligand Screening kit, a dye binds to the beta sheets of an aggregated amyloid peptide resulting in an intense fluorescent product (Ex/Em: 440/490 nm). In the presence of an Aβ42 ligand, this reaction is impeded/abolished resulting in decrease or total loss of fluorescence. This assay is useful in screening of Aβ42 ligands for developing potential therapeutic agents against Alzheimer’s disease. The assay is simple, reliable and high-throughput adaptable screening assay
产品特点
• Simple, highly sensitive, high-throughput compatible • Rapid screening of Aβ42 ligands • Kit includes the Aβ42 ligand control and a stable, Aβ42 peptide
